USP Says the Six-Peptide Policy Lacks Essential Quality Safeguards

The standards body whose compounding chapters anchor the federal draft peptide policy says the policy falls short on quality. In a November 3 statement from Rockville, Maryland, the United States Pharmacopeia said the HHS enforcement discretion policy covering six peptide bulk drug substances "does not include essential safeguards needed to help ensure the quality and safety of compounded preparations made with these substances." [1]

What USP said

The statement is short and specific. Its first point is identity: the six peptide bulk drug substances the policy covers "do not have USP–NF Monographs, USP Reference Standards, or established bulk drug substance name" from the recognized naming institutions (United States Adopted Names, International Nonproprietary Name, International Union of Pure and Applied Chemistry) "that define their identity and substance-specific quality attributes." [1]

Its second point is a finding: "USP's scientific review conducted in advance of the Pharmacy Compounding Advisory Committee meeting in July 2026 found that the peptide substances included under the HHS enforcement discretion policy are not sufficiently characterized to support consistent evaluation of their quality, creating a risk to patients." [1]

Its conclusion: "Without the clearly established identity and appropriate substance-specific standards and reference materials, the quality of the bulk drug substance cannot be reliably and consistently established." [1]

The gap inside the policy's own testing table

The draft policy is not indifferent to quality. Its third condition requires every covered bulk substance to come from a registered facility with a certificate of analysis whose test results match the criteria in the policy's Appendix B, covering identity, purity, potency and contaminants. [2]

Appendix B is a detailed testing table, and it leans on USP throughout. Its rows point to general chapters including USP <1503>, <621>, <467>, <232> and <233>, and its assay row requires high-performance liquid chromatography "based on comparison with an established quantitative reference standard." [2]

USP's statement draws the line those two facts create. General chapters describe methods, not substance-specific specifications: "The referenced USP standards in the policy cannot, on their own, provide adequate quality assurance for these peptide substances. They do not establish the substance- and product-specific quality specifications that would come from linking each peptide bulk drug substance to a drug monograph and related reference standard." [1]

The statute frames the same gap. Section 503A requires bulk substances to meet an applicable USP or NF monograph "if a monograph exists." For these six, none exists; the draft policy is the interim answer while the 503A bulks list is developed through rulemaking. [2][3]

A disagreement that predates the policy

The six substances (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500) were in Category 2 on FDA's bulks-list review track from September 2023 until April 22, 2026, a placement the policy itself notes never changed their status under section 503A. CDER recommended against listing each of them, and the Pharmacy Compounding Advisory Committee voted in favor of inclusion. [2]

USP's scientific review was prepared for that same July 2026 meeting. The statement does not relitigate the vote; it says the characterization gap the review identified remains the operative quality problem now that a policy has been drafted around these substances. [1]

The chronology since is quick. HHS announced the draft policy October 28, and the notice of availability published October 30 at 91 FR 68526. Comments on docket HHS-OASH-2026-0496 are open through November 13. The draft "does not establish any rights for any person and is not binding on HHS or the public," and the notice sets no date for a final version. [2][3]

What USP is not saying

The statement is careful about its own lane. USP is not claiming the regulator's seat: "neither existing nor potential new USP standards replace a regulator's role in determining whether a product is safe and effective." [1]

And closing the gap is not quick: "developing USP monographs and reference standards would require scientific information about the identity and quality attributes of these substances as well as official names determined by established naming institutions." [1]

The next scheduled forum for the same questions is FDA's next compounding advisory committee meeting, expected before the end of February 2027 with five more peptides (LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF) on the agenda and no exact date set, according to Peptide Policy Watch's tracking of the FDA committee page. [4]

"Without the clearly established identity and appropriate substance-specific standards and reference materials, the quality of the bulk drug substance cannot be reliably and consistently established."

What it means for a clinic: The quality question for the six policy peptides now has a named, on-the-record gap: no monographs, no official reference standards, no established names. If your pharmacy partners are preparing to compound any of the six under the draft policy, the concrete due-diligence question is how each lot's assay is validated when no official reference standard exists, because the policy's own Appendix B requires comparison with "an established quantitative reference standard." The draft is not a final policy or FDA approval, and comments on the docket are open through November 13.